Patricia Fulmer
Optometrist · Huntsville, ALNPI 1013340371
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (34.3%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by AbbVie at 57.2% of the total. Reporting peaked in 2022 at $20,557 and has fallen 91.8% since, to $1,691 in 2025. Among optometrist clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 216 payments — averaging $206.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$26K
- Carl Zeiss Meditec, Inc.$9K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$3K
- Carl Zeiss Meditec USA, Inc.$3K
- Tarsus Pharmaceuticals, Inc.$1K
- Lumenis BE Inc$1K
- plus $3K from 10 others
Across 2 payments — averaging $1640.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Topcon Healthcare, Inc.$3K
What the payments were for
- Consulting fees$15,32534%
- Speaking & faculty fees$12,95029%
- Travel & lodging$6,10414%
- Food & beverage$10,24723%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 87 | $25,516 |
| Carl Zeiss Meditec, Inc. | 22 | $8,948 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 32 | $2,850 |
| Carl Zeiss Meditec USA, Inc. | 8 | $2,669 |
| Tarsus Pharmaceuticals, Inc. | 5 | $1,032 |
| Lumenis BE Inc | 1 | $1,007 |
| Sun Pharmaceutical Industries Inc. | 21 | $709 |
| Alcon | 17 | $469 |
| Johnson & Johnson Vision Care, Inc. | 7 | $380 |
| Bausch & Lomb Americas Inc. | 7 | $358 |
| Novartis | 3 | $162 |
| Harrow Eye, LLC | 1 | $122 |
| Oyster Point Pharma, Inc. | 2 | $120 |
| Glaukos Corporation | 1 | $116 |
| Dompe US, Inc. | 1 | $106 |
| Shire North American Group Inc | 1 | $61 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VUITY$13,781
- CIRRUS HD-OCT$6,023
- FORUM$4,673
- CLARUS$4,373
- Humphrey HFA$3,273
- IOLMaster 700$2,273
- LUMIGAN$2,020
- BIOTRUE$1,382
- ULTRA$1,382
- RESTASIS MULTIDOSE$1,130
- M22$1,007
- CLARUS 500 Fundus Camera$1,000
- Glaucoma Workplace$1,000
- LASTACAFT$1,000
- ALPHAGAN P$986
- XDEMVY$900
- COMBIGAN$882
- CLARUS 500$800
- INFUSE$618
- CEQUA$456
How this compares
$44,626 in reported general payments places this provider in the 95th percentile of 749 optometrist providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MieboPerfluorohexyloctane/Pf | 24 | $17,247 |
| Latanoprost | 12 | $166 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo | $358 | $17,24724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 749 optometrist providers in Alabama.
Other optometrist in Huntsville
- Neena JamesHuntsville$74K
- Tracey Schroeder SwartzHuntsville$69K
- Mohammed HaqueHuntsville$10K
- Benjamin PendergrassHuntsville$9K
- Kristin SullinsHuntsville$7K
- Jessica BoydHuntsville$6K
- Alan PeasleeHuntsville$6K
- Kenneth MoultrieHuntsville$5K
- Mark SchaefferHoover$470K
- Kelly NicholsBirmingham$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.